PPARα: Its role in the human metabolic syndrome

Future Lipidology

Volumn 2, Issue 1, 2007, Pages 31-53

  Azhar, Salman ^a   Kelley, Glen ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Insmed Incorporated   (United States)

Author keywords

Adipose tissue; Cardiovascular disease; Dyslipidemia; Fatty acids; Glucose metabolism; Heart; Insulin resistance; Lipid homeostasis; Liver; Obesity; Pancreas; Skeletal muscle; Triglycerides; Type 2 diabetes

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ANTIDIABETIC AGENT; BEZAFIBRATE; BM170744; CLOFIBRIC ACID; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GW 7647; HARGLITAZAR; INDOMETACIN; LY 518674; MURAGLITAZAR; NAVAGLITAR; NONSTEROID ANTIINFLAMMATORY AGENT; NS 220; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; PIRINIXIC ACID; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TETRADECYLTHIOACETIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 34249289000     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.1.31     Document Type: Review

References (232)

1. Okrainec K, Banerjee DK, Eisenberg MJ: Coronary artery disease in the developing world. Am. Heart J. 148, 7-15 (2004).
2. American Heart Association: Heart disease and stroke statistics - 2005 update; Dallas, TX, USA. American Heart Association (2005).
3. Rashid MN, Fuentes F, Touchon RC, Wehner PS: Obesity and the risk for cardiovascular disease. Prev. Cardiol. 6, 42-47 (2003).
4. Scaglione R, Argano C, Di Chiara T, Licata G: Obesity and cardiovascular risk: The new public health problem of worldwide proportions. Expert. Rev. Cardiovasc. Ther. 2, 203-212 (2004).
5. Resnick HE, Howard BV: Diabetes and cardiovascular disease. Annu. Rev. Med. 53, 245-267 (2002).
6. Sobel BE, Schneider DJ: Cardiovascular complications in diabetes mellitus. Curr. Opin. Pharmacol. 5, 143-148 (2005).
7. Zimmet P, Alberti KGMM, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414, 782-787 (2001).
8. Bonow RO, GheorghAade M: The diabetes epidemic: a national and global crisis. Am. J. Med. 116(Suppl. 5A), S2-S10 (2004).
9. Engelgau MM, Geiss LS, Saaddine JB et al.: The evolving diabetes burden in the United States. Ann. Intern. Med. 140, 945-950 (2004).
10. Morrill AC, Chinn CD: The obesity epidemic in the United States. J. Public Health Policy 25, 353-366 (2004).
11. Haslam DW, James WP: Obesity. Lancet 366, 1197-1209 (2005).
12. Prentice AM: The emerging epidemic of obesity in developing countries. Int. J. Epidemiol. 35, 93-99 (2006).
13. Lillioja S, Mott DM, Spraul M et al.: Insulin resistance and insulin secretory dysfunstion as precursors of non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 1988-1992 (1993).
14. Goldstein BL: Fnsulin resistance: from benign to Type 2 diabetes mellitus. Rev. Cardiovasc. Med. 4(Suppi. 6), S3-S10 (2003).
15. DeFronzo RA: Pathogenesis of Type 2 diabetes mellitus. Med. Clin. North Am. 88, 787-835 (2004).
16. Kahn BB, Flier JS: Obesity and insulin resistance. J. Clin. Invest. 106, 473-481 (2000).
17. Lazar MA: How obesity cNuses diabetes: not a tall tale. Science 307, 373-375 (2005).
18. Despres J-P, Lamarche B, Mauriege P et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334, 952-957 (1996).
19. Pyorala M, Miettinen H, Laako M, Pyorala K: Hyperinsulinemia predicts coronary heart disease risk in healthy midddle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Circulation 98, 398-404 (1998).
20. Miegs JB: Epidemiology of the insulin resistance syndrome. Curr. Diab. Rep. 3, 73-79 (2003).
21. Reaven G: Role of insulin resistance in human diseasA (syndrome X): an expanded definition. Annu. Rev. Med. 44, 121-131 (1993).
22. Leslie BR: MetHbolic syndrome: historical perspective. Am. J. Med. Sci. 330, 264-268 (2005).
23. Kahn R, Buse J, FeTrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289-2304 (2005).
24. Sarafidis PA, NilsAon PM: The metabolic syndrome: a glance at its history. J. Hypertens. 24, 621-626 (2006).
25. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 265, 1415-1428 (2005).
26. Gill H, Mungo M, Whaley-Connell A, Stump C, Sowers JR: The key role of insulin resistance in the cardiometabolic syndrome. Am. J. Med. Sci. 330, 290-294 (2005).
27. Govindarajan G, Whaley-Connell A, Mungo M, Stump C, Sowers JR: The cardiometabolic syndrome as a cardiovascular risk factor. Am. J. Med. Sci. 330, 311-318 (2005).
28. Hafidh S, Senkottaiyan N, Villarreal D, Alpert MA: Management of the metabolic syndrome. Am. J. Med. Sci. 330, 343-351, (2005).
29. Miranda PJ, DeDronzo RA, Califf RM: Metabolic syndrome: definition, pathophysiology, and mechanisms. Am. Heart J. 149, 33-45 (2005).
30. Moller DE, KauAman KD: Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56, 45-62 (2005).
31. Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 47, 201-210 (2005).
32. Poole R, Byrne CD: The metabolic syndrome and type 2 diabetes. Minerva Endocrinol. 30, 139-159 (2005).
33. Grundy SM: MetCbolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. 47, 1093-1100 (2006).
34. Cameron AJ, Shaw JP, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 33, 351-375 (2004).
35. Ford ES, Giles WH, Mokdad AK: Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27, 2444-2449 (2004).
36. Haffner S, Taegtmeyer H: Epidemic obesity and the metabolic syndrome. Circulation 108, 1541-1545 (2003).
37. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Survey. JAMA 287, 356-359 (2002).
38. Alexender CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210-1214 (2003).
39. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH: Prevalence of a metabolic syndrome phenotype in aldolescents: Findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med. 157, 821-827 (2003).
40. Grundy SM: A constellation oT complications: the metabolic syndrome. Clin. Cornerstone 7, 36-45 (2005).
41. Ginsberg HN, Huang LS: The Insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J. Cardiovasc. Risk 7, 325-331 (2000).
42. Adams LA, Angulo P, Lindor KD: Nonalcoholic fatty liver disease. CMAJ 172, 899-905 (2005).
43. Marchesini G, Babini M: Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardiol. 54, 229-239 (2006).
44. McGarry JD: BantDng lecture 2001: dysregulation of fatty acid metabolism in the etiology of Type 2 diabetes. Diabetes 51, 7-18 (2002).
45. Goodpaster BH, Wolf D: Skeletal muscle lipid accumulation in obesity, insulin resistance, and Type 2 diabetes. Pediatric Diabetes 5, 219-226 (2004).
46. Borradaile NM, Schaffer JE: Lipotoxicity in the heart. Curr. Hypertens. Res. 7, 412-417 (2005).
47. Rhodes CJ: Type 2 diabetes - a matter of β-cell life and death? Science 307, 380-384 (2005).
48. Stumvoll M,PGoldstein B, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333-1346 (2005).
49. Zhang R, Liao J, Morse S, Donelon S, Reisin E: Kidney disease and the metabolic syndrome. Am. J. Med. Sci. 330, 319-325 (2005).
50. Rosmond R: Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 30, 1-10 (2005).
51. Wang M: The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr. Metab. 2, 3-16 (2005).
52. Unger WH: Minireview: weapons of Tean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144, 5159-5165 (2003).
53. Young LR, Nestle M: The contribution of expanding portion sizes to the US obesity epidemic. Am. J. Public Health 92, 246-249 (2002).
54. Bray GA, Popkin BM: Dietary fat intake does affect obesity. Am. J. Clin. Nutr. 68, 1157-1173 (1998).
55. Johnson RK, Frary C: Choose beverages and foods to moderate your intake of sugars: The 2000 dietary guidelines for Americans - what's all the fuss about? J. Nutr. 131, S2766-S2771 (2001).
56. Bray GA, Nielsen SJ, Popkin BM: Consumption of high-fructose corn syrup beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr. 79, 537-543 (2004).
57. Stone NJ, Saxon D: Approach to treatment of the patient with metabolic syndrome: Lifestyle therapy. Am. J. Cardiol. 96, E15-E21 (2005).
58. Corella D, OrdovasAJM: The metabolic syndrome: a crossroad for genotype-phenotype associations in atherosclerosis. Curr. Atheroscler. Rep. 6, 186-196 (2004).
59. Roche HM, PhillipsTC, Gibney MJ: The metabolic syndrome: the crossroads of diet and genetics. Proc. Nutr. Soc. 64, 371-377 (2005).
60. Wisse BE: The inflammTtory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15, 2792-2800 (2004).
61. Hutley L, Prins JB: FRt as an endocrine organ: relationship to the metabolic syndrome. Am. J. Med. Sci. 330, 280-289 (2005).
62. Hitzenberger K, Richter-Quittner M: Ein Beitrag zum Stoffwechsel bei der vaskulären Hypertonie. Weiner Arch Innere Med. 2, 189-216 (1921).
63. Hitzenberger K: Über den Blutdruck bei Diabetes Mellitus. Weiner Arch Innere Med. 2, 461-466 (1921).
64. Kylin E: Hypertonie and Zuckerkrankheit. Zentralblatt für Innere Medizin 42, 873-877 (1921).
65. Marañon G: Über Hypertonie and Zuckerkrankheit. Zentralblatt für Innere Medizin 43, 169-176 (1922).
66. Kylin E: Studien über das Hypertoni-Hyperglycemi-Hyperurikmi syndrom. Zentralblatt für Innere Medizin 44, 105-112 (1923).
67. Himsworth H: Aiabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1, 127-130 (1936).
68. Vague J: La differenciation sexuelle. Facteur determinant des formes de l' obésite. Presse Méd. 55, 339-340 (1947).
69. Vague J: The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am. J. Clin. Nutr. 4, 20-34 (1956).
70. Albrink MJ, Meigs, JW: Interrelationship between skinfold thickness, serum lipids and blood sugar in normal men. Am. J. Clin Nutr. 15, 255-261 (1964).
71. Cámus JP: Goutte, diabèteU hyperlipémie: un trisyndrome métabolique. Rev. Rhum. 33, 10-15 (1966).
72. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR: Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1, 1336-1337 (1966).
73. Avogaro P, Crepaldi G: Plurimetabolic syndrome. Acta Diabetol. Lat. 4, 572-580 (1967).
74. Mehnert H, Kuhlmann H: Hypertonie und diabetes mellitus. Dtsch Med. J. 19, 567-571 (1968).
75. Hansfeld M, Leonhardt W: Das metabolische syndrom. Dt. Gesundh-Wesen 36, 545-551 (1981).
76. Krotkiewski M, Björntorp P, Sjöström L, Smith U: Impact of obesity on metabolism in men and women: Importance of regional adipose tissue distribution. J. Clin. Invest. 72, 1150-1162 (1983).
77. Bjorntorp P: Metabolic implications of body fat distribution. Diabetes Care 14, 1132-1143 (1991).
78. Kissebah AH, Vydelingum N, Murray R et al.: Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 54, 254-260 (1982).
79. Modan M, HalAin H, Almog S et al.: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J. Clin. Invest. 75, 809-817 (1985).
80. DeFronzo RA, Simonson D, Ferrannini E: Hepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23, 313-319 (1982).
81. Ferrannini E, Buzzigoli G, Bonadonna R et al.: Insulin resistance in essential hypertension. N. Engl J. Med. 317, 350-357 (1987).
82. Wingard DL, Barret-Connor E, Criqui MH, Suarez L: Clustering of heart disease risk factors in diabetes compared to non-diabetic adults. Am. J. Epidemiol. 117, 19-26 (1983).
83. Reaven GM: BantiRg lecture 1988: role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
84. Kaplan NM: TheUdeadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 149, 1514-1520 (1989).
85. DeFronzo RA, FArrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173-194 (1991).
86. Zimmet PZ: Kelly West lecture 1991. Challenges in diabetes epidemiology - from west to the rest. Diabetes Care 15, 232-252 (1992).
87. Hjerrmann I: The metabolic cardioSascular syndrome: syndrome X, Reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome. J. Cardiovasc. Pharmacol. 20(Suppl. 8), S5-S10 (1992).
88. Grundy SM, Cleeman JI, Daniels SR et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752 (2005).
89. Ferrannini ET Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34, 416-422 (1991).
90. Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol. Metab. Clin. North Am. 33, 283-303 (2004).
91. Pouliot MC, Despres JP, Lemieux S et al.: Waist circumference and abdominal saggital diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. 73, 460-468 (1994).
92. Lemieux I, Pascot A, Couillard C et al.: Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia: hyperapolipoprotein B; small, dense LDL) in men? Circulation 102, 179-184 (2000).
93. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch. Intern. Med. 163, 427-436 (2003).
94. Carr DB, Utzschneider KM, Hull RL et al.: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment III criteria for the metabolic syndrome. Diabetes 53, 2087-2094 (2004).
95. Meigs JB, D'Agostina RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: The Framingham Offspring Study. Diabetes 46, 1594-1600 (1997).
96. Hanley AJ, Karter AJ, Festa A et al.: Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes 51, 2642-2647 (2002).
97. Alberti KGMM, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062 (2005).
98. Reaven G: Insulin resistance, Type 2 diabetes mellitus, and cardiovascular disease: The end of the beginning. Circulation 112, 3030-3032 (2005).
99. Gustat J, Srinivasan SR, Elkasabany A, Berenson GS: Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: The Bogalusa Heart Study. J. Clin. Epidemiol. 55, 997-1006 (2002).
100. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929-1935 (2004).
101. American Diabetes Association: Consensus Development Conference on Insulin Resistance. 5-6 November 1997. Diabetes Care 21, 310-314 (1998).
102. Alberti KG, Zimmet PZ: Definition, diagnosis and its complications, part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539-553 (1998).
103. Definition, Diagnosis and Classification of Diabetes Mellitus and its complications. Geneva, Switzerland: Department of Noncommunible Disease Surveillance. World Health Organization (1999).
104. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Metab. 16, 442-443 (1999).
105. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
106. Einhorn D, Reaven GM, Cobin RH et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237-252 (2003).
107. Grundy S, Brewer HB, Cleeman J, Smith SC, Lenfant C: For the conference participants. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association on scientific issues related to definition. Circulation 109, 433-438 (2004).
108. Gotto AM Jr, Blackburn GL, Dailey GE III et al.: The metabolic syndrome: A call to action. Coron. Artery Dis. 17, 77-80 (2006).
109. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688 (1999).
110. Lee C-L, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144, 2201-2207 (2003).
111. WillsFn TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550 (2000).
112. Berger J, Moller DE: The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435 (2002).
113. Francis GA, Fayard E, Picard F, Auwerx J: Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65, 261-311 (2003).
114. Ferré P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl. 1), S43-S50 (2004).
115. Tham DM, Wang Y-X, Rutledge JC: Modulation of vascular inflammation by PPARs. Drug News Perspect. 16, 109-116 (2003).
116. Castrillo A, Tontonoz P: Nuclear reAeptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20, 455-480 (2004).
117. Kosadinova R,CWahli W, Michalik L: PPARs in diseases: control mechanisms of inflammation. Curr. Med. Chem. 12, 2995-3009 (2005).
118. Chen YE, Fu M, Zhang J et al.: Peroxisome proliferator-activated receptors and cardiovascular system. Vit. Horm. 66, 157-188 (2003).
119. Marx N, Duez H, Fruchart J-C, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ. Res. 94, 1168-1178 (2004).
120. Li AC, Palinski W: Peroxisome proliferaHor-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu. Rev. Pharmacol. Toxicol. 46, 1-39 (2006).
121. Lefebvre P, Chinetti G, Fruchart J-C, Staels B: Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571-580 (2006).
122. Semcple RK, Chatterjee VK, O'Rahilly S: PPARγ and human metabolic disease. J. Clin. Invest. 116, 581-589 (2006).
123. BaAish GD, Narkar VA, Evans RM: PPARδ: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590-597 (2006).
124. Guan Y-F, Breyer MD: Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 60, 14-30 (2001).
125. Mandard S, Müller M, Kersten S: Peroxisome proliferator-activated receptor α target genes. Cell. Mol. Life Sci. 61, 393-416 (2004).
126. Reddy JK: Peroxisome proliferators and peroxisome proliferators-activated receptor α. Biotic and xenobiotic sensing. Am. J. Pathol. 164, 2305-2321 (2004).
127. Barbier O, Torra P, Duguay Y et al.: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22, 717-726 (2002).
128. Hsu M-H, Palmer CAN, Song W, Griffin KJ, Johnson EF: A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J. Biol. Chem. 273, 27088-27997 (1998).
129. Privalsky ML: The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu. Rev. Physiol. 66, 315-360 (2004).
130. Chakravarthy MV, Pan Z, Zhu Y et al.: 'New' hepatic fat activates PPARα to maintain glucose, lipid and cholesterol homeostasis. Cell Metab. 1, 309-322 (2005).
131. Spiegelman BM, Heinrich R: Biological control through regulated transcriptional coactivators. Cell 119, 157-167 (2004).
132. Bishop-Bailey D: Peroxisome proliferator-activated receptors in the cardiovascular system. Brit. J. Pharmacol. 129, 823-834 (2000).
133. Akiyama PE, Meinke PT, Berger JP: PPAR ligands: potential therapies for metabolic syndrome. Curr. Diab. Rep. 5, 45-52 (2005).
134. Kuwabara K, Murakami K, Todo M et al.: A novel selective peroxisome proliferator-activated α-agonist,
135. Pelton PD, Patel M, Demarest KT: Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr. Top. Med. Chem. 5, 265-282 (2005)
136. Staels B, Fruchart J-C: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54, 2460-2470 (2005).
137. Israelian-Konaraki Z, Reaven PD: Peroxisome proliferators-activated receptor-α and atherosclerosis: From basic mechanisms to clinical implications. Cardiology 103, 1-9 (2005).
138. Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D: Role of PPAR-γ agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: A cardiovascular perspective. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5, 377-386 (2005).
139. Aasum E, Belke DD, Severson DL et al.: Cardiac function and metabolism in the Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-α activator. Am. J. Physiol. Heart Circ. Physiol. 283, H949-H957 (2002).
140. Schäfer SA, Hansen BC, Vǒlkl A, Fahimi HD, Pill J: Biochemical and morphological effects of K-111, a peroxisome proliferator-actvated receptor (PPAR)α activator. Biochem. Pharmacol. 68, 239-251 (2004).
141. Cheng PT, Mukherjee R: PPARs as targets for metabolic and cardiovascular diseases. Mini Rev. Med. Chem. 5, 741-753 (2005).
142. Brandt JM, Djouadi F, Kelley DP: Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor α. J. Biol. Chem. 273, 23786-23792 (1998).
143. Mascaró C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro, D: Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferators-activated receptor. J. Biol. Chem. 273, 8560-8563 (1998).
144. Barrero MJ, Camarero N, Marrero PF, Haro D: Control of human carnitine palmitoyltransferase II gene transcription by peroxisome-activated receptor through a partially conserved proliferator proliferator-responsive element. Biochem. J. 369, 721-729 (2003).
145. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP: The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl Acad. Sci. USA 91, 11012-11016 (1994).
146. Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D: Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269, 18767-18772 (1994).
147. Lee SS-T, Pineau T, Drago J et al.: Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 3012-3022 (1995).
148. Zhang B, Marcus SL, Sajjadi FG et al.: Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal anoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc. Natl Acad. Sci. USA 89, 7541-7545 (1992).
149. Nicolas-Frances V, Dasari VK, Abruzzi E, Osumi T, Latruffe N: The peroxisome proliferator response element (PPRE) present at positions -681/-669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPARα and HNF-4. Biochem. Biophys. Res. Comunn. 269, 347-351 (2000).
150. Aldridge TC, Tungwood JD, Green S: Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem. J. 306, 473-479 (1995).
151. Peters JM, Hennuyer N, Staels B et al.: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J. Biol. Chem. 272, 27307-27312 (1997).
152. Aoyama T, Peters JM, Iritani N et al.: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα,). J. Biol. Chem. 273, 5678-5684 (1998).
153. Costet P, Legerdre C, More J, Edger A, Galtier P, Pineau T: Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273, 29577-29585 (1998).
154. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S: The mouse peroxisome, proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11, 433-439 (1992).
155. Kersten S, Seydoux J, Petes JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489-1498 (1999).
156. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473-7478 (1999).
157. Huss JM, Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ. Res. 95, 568-578 (2004).
158. Riby JE, Fujisawa T, Kretchmer N: Fructose absorption. Am. J. Clin. Nutr. 58, S748-S753 (1993).
159. Aoyama Y, Yoshida A, Ashida K: Effect of dietary fats and fatty acids on the liver lipid accumulation induced by feeding a protein-repletion diet containing fructose to protein-depleted rats. J. Nutr. 104, 741-746 (1974).
160. Jurgens H, Hass W, Castaneda TR et al.: Consuming fructose-sweetened beverages increases body adiposity in mice. Obes. Res. 13, 1146-1156 (2005).
161. Nagai Y, Nishio Y, Nakamura T, Maegawa H, Kikkawa R, Kashiwagi A: Amelioration of high fructose-induced metabolic derangements by activation of PPARα. Am. J. Physiol. Endocrinol. Metab. 282, E1180-E1190 (2002).
162. Kelley GL, Allan G, Azhar S: High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology 145, 548-555 (2004).
163. Wei Y, Wang D, Pagliassotti MJ: Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. J. Nutr. 135, 1642-1646 (2005).
164. Basciano H, Federico L, Adeli K: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr. Metab. (Lond.). 2, 5 (2005).
165. Berger PM, Kelly DP: PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10, 238-245 (2000).
166. Djouadi F, Brandt J, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelley DP: The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids 60, 339-343 (1999).
167. Watanabe K, Fujii H, Takahashi T et al.: Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity. J. Biol. Chem. 275, 22293-22299 (2000).
168. Campbell FM, Kozak R, Wagner A et al.: A role for PPARa° in the control of cardiac malonyl-CoA levels: Reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARα are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J. Biol. Chem. 277, 4098-4103 (2002).
169. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473-7478 (1996).
170. Finck BN, Lehman JJ, Leone TC et al.: The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109, 121-130 (2002).
171. Finck BN, Han X, Courtois M et al.: A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proc. Natl Acad. Sci. USA 100, 1226-1231 (2003).
172. Park S-Y, Cho Y-R, Fink BN et al.: Cardiac-specific overexpression of peroxisome proliferator-activated receptor-α causes insulin resistance in heart and liver. Diabetes 54, 2514-2524 (2005).
173. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP: Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723-1730 (2000).
174. Young ME, Laws FA, Goodwin GW, Taegtmeyer H: Reactivation of peroxisome proliferator-activated receptor α is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276, 44390-44395 (2001).
175. Huss JM, Levy FH, Kelly DP: Hypoxia inhibits the PPARα/RXR gene regulatory pathway in cardiac myocytes. J. Biol. Chem. 276, 44390-44395 (2001).
176. Razeghi P, Young ME, Abbasi S, Taegtmeyer H: Hypoxia in vivo decreases peroxisome proliferator-activated receptor α-regulated gene expression in rat heart. Biochem. Biophys. Res. Commun. 287, 5-10 (2001).
177. Kelley DP: PPATs of the heart: there is a crowd. Circ. Res. 92, 482-484 (2003).
178. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: Expression of putative fatty acid transport genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273, 16710-16714 (1998).
179. van der Vliet HN, Schaap FG, Levels JH et al: Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295, 1156-1159 (2002).
180. Schultze A, Alborn WE, Mewton RK, Konrad RJ: Administration of PPARα agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. J. Lipid Res. 46, 1591-1595 (2005).
181. Prieur X, Schapp FG, Coste H, Rodríguez JC: Hepatocyte nuclear factar-4α regulates the human apolipoprotem AV gene: Identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-γ coactivator-1a, AMP-activated protein kinase, and mitogen-activated protein kinase pathway. Mol. Endocrinol. 19, 3107-3125 (2005).
182. Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodríguez JC: Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J. Biol. Chem. 260, 27533-27543 (2005).
183. Dobbins RL, Chester MW, Stevenson BE, Daniels MB, Stein DT, McGarry JD: A fatty acid-dependent step is critically important for both glucose- and non-glucose-stimulated Insulin secretion. J. Clin. Invest. 101, 2370-2376 (1998).
184. Wollheim CB, Maechler P: β-cell mitochondria and insulin secretion: messenger role of nucleotides and metabolites. Diabetes 51(Suppl. 1), S37-S42 (2002).
185. Yaney GC, Corkey BE: Fatty acid metabolism and insulin secretion in pancreatic β cells. Diabetologia 46, 1297-1312 (2003).
186. Sugden MC, Holmes MJ: Potential role of peroxisome proliferator-activated receptor-α in the modulation of glucose-stimulated insulin secretion. Diabetes 53 (Suppl. 1), S71-S81 (2004).
187. Zhou Y-T, Shimabukuro M, Wang M-Y et al.: Role of peroxisome proliferator-activated receptor α in disease of pancreatic β-cells. Proc. Natl Acad. Sci. USA 95, 8898-8903 (1998).
188. Roduit R, Morin J, Massé F et al.: Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-1 gene in the pancreatic β-cell. J. Biol. Chem. 275, 35799-35806 (2000).
189. Gremlich S, Nolan C, Roduit R et al.: Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor α transcription up-regulation of fatty acid oxidation. Endocrinology 146, 375-382 (2005).
190. Ravnskjaer K, Boergesen M, Rubi B et al.: Peroxisome proliferator-activated receptor α (PPARα) potentiates, whereas PPARγ attenuates, glucose-stimulated insulin secretion in pancreatic β-cells. Endocrinology 146, 3266-3276 (2005).
191. Guerre-Millo M, Gervois P, Raspe E et al.: Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638-16642 (2000).
192. Sugden MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ: Peroxiosme-proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem. J. 364, 361-368 (2002).
193. Ye J-M, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR γ activation. Diabetes 50, 411-417 (2001).
194. Chou CJ, Haluzik M, Gregory C et al.: WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatropic A-ZIP/F-1 mice. J. Biol. Chem. 277, 24484-24489 (2002).
195. Koh EH, Kim MS, Park JY et al.: Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: comparison with PPAR-γ activation. Diabetes 52, 2331-2337 (2003).
196. Guan Y: Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15, 2801-2815 (2004).
197. Li AC, Binder C, Gutierrez A et al.: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J. Clin. Invest. 114, 1564-1576 (2004).
198. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL: Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol. Cell. Biochem. 285, 35-50 (2006).
199. Sugden MC, Greenwood GK, Smith ND, Holness MJ: Peroxisome proliferator-activated receptor-α activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in β-cell glucose sensing and responsiveness. Endocrinology 144, 146-153 (2003).
200. Plutzky J: The potential role of peroxisome proliferator-activated receptors on inflammation in Type 2 diabetes mellitus and atherosclerosis. Am. J. Cardiol. 92, 34-41 (2003).
201. Bloomgarden ZT: Inflammation, atherosclerosis, and aspects of insulin action. Diabetes Care 28, 2312-2319 (2005).
202. Lusis AJ: Atherosclerosis. Nature 407, 233-241 (2000).
203. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
204. Beaven SW, Tontonoz P: Nuclear reTeptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57, 313-329 (2006).
205. Blaschke F, Takata Y, Caglayan E et al.: Obesity, peroxisome proliferator activated receptor, and atherosclerosis in Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26, 28-40 (2005).
206. Skalen K, Gustafsson M, Rydberg EK et al.: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417, 750-754 (2002).
207. Inoue I, Shino K, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246, 370-374 (1998).
208. Staels B, Koening W, Habib A, Merval R, Lebret M, Torra IP: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790-793 (1998).
209. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z: Activation of proliferator-activated receptor α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573-25580 (1998).
210. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101, 2411-2417 (2000).
211. Zhu L, Bisgaier CL, Aviram M, Newton RS: 9-Cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. Arterioscler. Thromb. Vasc. Biol. 19, 2105-2111 (1999).
212. Delerive P, Martin-Nizard F, Chinetti G et al.: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85, 394-402 (1999).
213. Jackson SM, Parhami F, Xi XP et al.: Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19, 2094-2104 (1999).
214. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99, 3125-3131 (1999).
215. Shu H, Wong B, Zhou G et al.: Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 267, 345-349 (2000).
216. Chinetti G, Lestavel S, Bocher V et al.: PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7, 53-58 (2001).
217. Neve BP, Corseaux D, Chinetti G et al.: PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103, 207-212 (2001).
218. Marx N, Mackman N, Schonbeck U et al.: PPARα activators inhibit tissue factor expression and activity in human monocytes. Circulation 103, 213-219 (2001).
219. Delerive P, De Bosscher K, Vanden-Berghe W, Fruchart JC, Haegeman G, Staels B: DNA binding-independent induction of IκBα gene transcription by PPARα. Mol. Endocrinol. 16, 1029-1039 (2002).
220. Delerive P, De Bosscher K, Besnard S, Vanden-Berghe W, Peters JM, Gonzalez FJ: Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274, 32048-32054 (1999).
221. Poynter ME, Daynes RA: Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273, 32833-32841 (1998).
222. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B: Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIB. Int. J. Clin. Pharmacol. Ther. 36, 345-349 (1998).
223. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S: Peroxisome proliferator-activated receptor a agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 658-663 (2004).
224. Loscalzo J: Nitric oxide and vascular tone. N. Engl. J. Med. 333, 251-253 (1995).
225. De Caterina R, Libby P, Peng HB et al.: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96, 60-68 (1995).
226. Li AC, Glass CG: PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45, 2161-2173 (2004).
227. Devchand PR, Keller H, Peters JM, Vasquez M, Gonzalez FJ, Wahli W: The PPARα-leukotriene B4 pathway to inflammation. Nature 384, 23-24 (1996).
228. Cuzzocrea S, Mazzon E, Di Paola R et al.: The role of the peroxisome proliferators-activated receptor-α (PPAR-α) in the regulation of acute inflammation. J. Leukoc. Biol. 79, 999-1010 (2006).
229. Tordjman K, Bernal-Mizrachi C, Zemany L et al.: PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107, 1025-1034 (2001).
230. Fu T, Kashireddy P, Borensztajn J: The peroxisome proliferator-activated receptor α against ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373, 941-947 (2003).
231. Claudel T, Leibowitz MD, Fievet C et al.: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl Acad. Sci. USA 98, 2610-2615 (2001).
232. Duez H, Chao YS, Hernandez G et al.: Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J. Biol. Chem. 277, 48051-48057 (2002).